EMERYVILLE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced it will release its second quarter 2008 financial results, for the quarter ended December 31, 2007, on February 11. The Company will host a conference call to discuss the earnings and to give a corporate update.
Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Craig W. Carlson, Vice President and Chief Financial Officer. The details for the call are as follows:
http://investor.shareholder.com/ntii/events.cfm
About Neurobiological Technologies, Inc.
NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.
CONTACT: Walter Kass of Cordon Partners, LLC., +1-212-300-4708, for
Neurobiological Technologies, Inc.
Web site: http://www.ntii.com/
